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The effect of cigarette smoking on asthma control
during exacerbations in pregnant women
Vanessa E Murphy,1 Vicki L Clifton,2 Peter G Gibson3
ABSTRACT
Background Smoking and severe asthma exacerbations
in pregnancy are risk factors for low birth weight babies.
No studies have assessed the clinical implications of
smoking on asthma exacerbations in pregnancy.
Methods Pregnant women with current asthma (n¼80)
were prospectively assessed at clinic visits (18, 30,
36 weeks), during exacerbations and with fortnightly
phone calls. The asthma control questionnaire was
administered at each contact and exacerbations classified
as severe (requiring medical intervention) or mild
(self-managed). Medications, self-management skills,
smoking history, fractional exhaled nitric oxide (FENO),
exhaled carbon monoxide (ECO) and lung function were
assessed. Pregnant women without asthma (controls,
n¼46) were assessed prospectively at clinic visits.
Results Women with asthma were more likely to smoke
(34% current smokers) than women without asthma
(15% current smokers). In women with asthma, the
median (IQR) exacerbation rate during pregnancy was
2.0 (1.0e3.0) in current smokers, 2.0 (1.0e3.0) in
ex-smokers and 1.5 (1.0e2.0) in never smokers. The
asthma control score during exacerbations was higher in
current smokers (median (IQR) 2.17 (1.17e2.7))
compared with never smokers (1.17 (0.8e2.17),
p¼0.056). An adjusted linear regression model found that
smoking was significantly associated with higher asthma
control score during exacerbation (p¼0.04). Birth weights
were lower among children of smokers than non-smokers
(p¼0.023 control group, p¼0.086 asthma group).
Conclusions During pregnancy, asthma exacerbations
are more common and more severe in current smokers
than never smokers. The risk of effects of maternal
asthma on the fetus may be greater among smokers.
INTRODUCTION
Smoking during pregnancy is a signiﬁcant risk
factor for poor perinatal outcomes, including low
birth weight, premature birth and infant
mortality.1 Despite this, many pregnant women
continue to smoke during pregnancy. In Australia,
the rate of smoking among pregnant women is
w20%, and the quit rate in pregnancy is surpris-
ingly low, with heavy smokers less likely to quit.2
Studies from around the world have suggested that
pregnant women with asthma are more likely to
smoke than pregnant women without asthma,3e14
with few exceptions.15e17 Women with asthma are
also at an increased risk of low birth weight,18 and
severe asthma exacerbations during pregnancy are
associated with a 2.5-fold increased risk of low
birth weight.19 Thus, women with asthma who
smoke during pregnancy may be at increased risk of
low birth weight from the combined effects of
smoking, asthma and severe asthma exacerbations.
There is also the potential for smoking to worsen
asthma control during pregnancy, and further
increase risks to the fetus. Smoking is associatedwith
persistent changes in asthma, including a greater
decline of lung functionwith age,20 poorer symptom
control21 and reduced response to corticosteroids.22
It was previously found that asthma control
among non-pregnant adult smokers was worse than
in non-smokers21 and that smokers had signiﬁcantly
higher scores for each individual item than never
smokers, with the exception of lung function.21
There are limited studies investigating the frequency
or severity of exacerbations among smokers with
asthma compared with non-smokers with asthma,
with some evidence that current smokers report
more frequent symptoms,23 and may have a higher
risk for hospitalisation for acute asthma.24
Asthma control and exacerbations have not
previously been assessed in smokers during preg-
nancy. We hypothesised that pregnant women
with asthma who were current smokers would
experience more frequent exacerbations than never
smokers, and that these exacerbations would be
more severe, indicated by a higher asthma control
questionnaire (ACQ) score.
METHODS
Pregnant women (18e43 years) were consecutively
recruited through the John Hunter Hospital ante-
natal clinics and the community between July 2004
and December 2006. Women signed written
informed consent for participation. Approval was
provided by the University of Newcastle and
Hunter New England Health Human Research
Ethics Committees. A research midwife located in
the antenatal clinic explained the study to poten-
tially eligible participants, and referred those
potentially interested to research staff who
obtained written informed consent. This approach
allowed prospective recruitment of consecutive
new referrals to the antenatal clinic.
Pregnant women with physician-diagnosed
asthma (n¼85) were prospectively followed from
recruitment (mean 14.8, SD (3.0) weeks gestational
age) with clinic visits at w18, 30 and 36 weeks
gestation (visit 1, 2 and 3), and fortnightly phone
calls between visits. Women were assessed during
exacerbation where possible. Four women with
asthma did not have current symptoms or medi-
cation use during the pregnancy and were consid-
ered in remission. One woman completed one visit
and insufﬁcient data about smoking status were
available. Results from these ﬁve women were
excluded from the present analysis.
The ACQ625 was administered at each contact.
The ACQ is a validated tool assessing the severity
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of night waking, morning asthma symptoms, activity limita-
tion, shortness of breath, wheeze, short acting b2-agonist use
and lung function.25 26 This shortened version did not include
the lung function item, allowing us to administer the ques-
tionnaire at both telephone contacts and clinic visits. A higher
score indicates worse asthma control. Asthma exacerbations
were assessed prospectively during the study visits and phone
calls, and retrospectively for the ﬁrst part of pregnancy, with
details conﬁrmed by the medical records. Severe exacerbations
were deﬁned as requiring medical intervention (hospital admis-
sion, emergency department presentation, unscheduled doctor
visit or the use of oral corticosteroids (OCS)). Mild exacerbations
were deﬁned as those managed by the subject and self-reported
as increased symptoms or medication use (inhaled corticoste-
roids (ICS) or b2-agonists), or using a written action plan.
During clinical assessments, we measured height, weight,
lung function (Spirotrac IV, Vitalograph, Buckingham, UK),
fractional exhaled nitric oxide (FENO; NIOX, Aerocline, Solan,
Sweden) at a controlled ﬂow rate of 50 ml/s according to
American Thoracic Society guidelines, and exhaled carbon
monoxide (ECO; piCO Smokerlyzer Breath CO Monitor,
Bedfont, UK). Asthma history, smoking history (past and
current, and passive smoke exposure; see online supplement),
medication use and self-management skills were assessed by
direct questioning, as described previously.27 Self-management
skills were assessed by a trained asthma educator and included
observed inhalation device technique, self-monitoring of symp-
toms and/or peak ﬂow, written action plan use and under-
standing, medication adherence and knowledge of asthma and
its treatment. Asthma severity was classiﬁed as mild, moderate
or severe using an integrated severity score from the Australian
National Asthma Council guidelines based on symptoms,
previous exacerbation frequency and severity, and lung function
(see online supplement).28 ICS use was expressed as mg/day of
beclomethasone dipropionate (BDP) equivalents, where 1 mg/
day BDP was equivalent to 1 mg/day budesonide, and 0.5 mg/
day ﬂuticasone dipropionate. Some women used ICS in combi-
nation with long-acting b-agonists (LABAs) either budesonide/
formoterol or ﬂuticasone/salmeterol. Details on marital status
and infant outcomes were obtained from medical records.
During phone calls and clinic visits, subjects were asked about
symptom frequency (days in past week with night waking,
morning symptoms or activity limitation due to asthma),
medication use and exacerbations in the past fortnight. Women
with current exacerbations were offered an additional clinic
visit, where assessments were repeated.
Pregnant women with no diagnosis of asthma (n¼46) were
prospectively followed from recruitment (mean 14.1 (3.1)
weeks) with clinic visits only, at w18, 30 and 36 weeks gesta-
tion, and height, weight, smoking history, spirometry, FENO
and ECO were assessed.
Results are presented as mean6SD or median (IQR) as
appropriate. Statistical analysis was performed using GraphPad
Instat 3.05 (GraphPad Software, San Diego, California, USA)
and Stata 7 (StataCorp, College Staion, Texas, USA). Group
differences were analysed using analyisis of variance (ANOVA)
or KruskaleWallis tests for normal or non-normally distributed
data, respectively. Post hoc testing was done using the
TukeyeKramer (for ANOVA) or Dunn tests (for KruskaleWallis
tests). Proportions were compared using the c2 statistic or the
Fisher exact test. Linear and Poisson regression models were used
to test the association between smoking and asthma control,
and between smoking and asthma exacerbation rates. Additional
potential explanatory variables were included in the model and
chosen based on demographics (age, marital status), prior
known association between the variable and asthma control
(asthma severity, ICS use), and to adjust for potential
confounding (body mass index (BMI), marital status). ACQ6
was transformed using the square root to provide normality, and
the robust cluster option was used to adjust for subjects




Women with asthma were divided into three groups based on
self-reported smoking status (26 never smokers, 27 ex-smokers
and 27 current smokers). Current smokers were signiﬁcantly
more likely to be single than never or ex-smokers (p¼0.001), had
lower body weight than ex-smokers (p¼0.046) and had lower
FENO than ex-smokers (p¼0.018). Lung function was not
signiﬁcantly different between the groups and there was no
signiﬁcant difference in either the ﬁrst stable ACQ6 or lowest
ACQ6 value recorded in each group (data not shown). The
asthma pattern was severe in 26% of current smokers, 29.6% of
ex-smokers and 15.4% of non-smokers (table 1).
Current smokers with asthma reported 4 (2.3e7.9) pack-years
(8.5 years total smoking) and smoked 5e6 cigarettes per day at
each visit, and 5 (4e10) cigarettes/day during the exacerbation
visit. Ex-smokers with asthma reported a median (IQR) smoking
history of 2.1 (1.5e5.8) pack-years (9 years total smoking), and
had quit a median of 1.3 years earlier (range 0e15 years). There
Table 1 Baseline characteristics of subjects
Asthma Control
Never smokers Ex-smokers Current smokers
p Value
Never smokers Ex-smokers Current smokers
p Valuen[26 n[27 n[27 n[24 n[15 n[7
Maternal age (years) 28.764.2 27.664.5 26.465.9 NS 30.063.7* 26.866.0 23.365.3 0.005
Gravidity 2.5 (1e4) 3 (1e3) 3 (2e4) NS 1.5 (1e3) 2 (1e2) 2 (1e5) NS
Parity 1 (0e2) 0 (0e1) 1 (0e2) NS 0 (0e1) 0 (0e1) 0 (0e3) NS
Weight (kg) 75.3614.7 80.1621.2* 67.3612.1 0.046 81.8617.8 73.9618.4 82.1619.8 NS
BMI (antenatal) 27.865.3 29.266.7 25.264.8* NS 28.965.0 28.166.4 32.067.3 NS
% Single 1 (4%)* 4 (15%) 12 (46%) 0.001 1 (4%)* 1 (8%) 4 (57%) 0.007
% predicted FEV1 96.0614.0 92.4614.6 92.3615.1 NS 99.7613.2 94.9613.3 10268.4 NS
% predicted FVC 101.2611.7 99.8612.3 99.1615.5 NS 106613.4 92.9627.0 108.9610.5 NS
Lowest FENO (ppb) 13 (10.1e19.6) 17.9 (9e30.8)* 8.3 (6.6e16.9) 0.018 10.2 (7.0e13.7) 10.1 (8.1e14.9) 7.8 (7.0e10.0) NS
ECO at visit 1 1 (1e1)* 1 (1e2)* 9.5 (4.5e17.5) 0.0001 1 (1e1)* 1 (1e2)* 15 (7e22) 0.0001
Values are mean 6 SD, median (IQR) or n (%) of subjects in each group.
*Post hoc test significant p<0.017 vs current smokers.
BMI, body mass index; ECO, exhaled carbon monoxide; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NS, not significant.
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were no differences between the smoking groups in reported
medication use or adherence during exacerbations (online
supplement); however, current smokers had non-signiﬁcantly
poorer asthma medication knowledge.
Control group
The control group of pregnant women without asthma
consisted of 24 never smokers, 15 ex-smokers and 7 current
smokers. The current smokers were signiﬁcantly younger
(p¼0.005) and were more likely to be single than never and ex-
smokers (p¼0.007). Control smokers had signiﬁcantly higher
ECO than never or ex-smokers (p¼0.0001). Current smokers
reported 3.8 (2.3e5.4) pack-years (9.5 years total smoking) and
smoked 3e8 cigarettes per day at each visit. The ex-smokers in
the control group reported a smoking history of 1.9 (1.2e3)
pack-years (6 years total smoking) and had quit smoking
a median of 1 year earlier (range 0e21 years).
Passive smoking exposure
Among women with asthma, current smokers were more likely
to have a partner who smoked (p¼0.001), allow smoking
indoors (p¼0.002, c2 test for trend) and have regular visitors
who smoked indoors (1e7 times per week, p¼0.03, c2 test for
trend) or outdoors (1e7 times per week, p¼0.001) than never or
ex-smokers (table 2).
In the control group, there was a similar trend for more
current smokers to have a partner who smoked (p>0.05), and
current and ex-smokers were more likely to have regular visitors
who smoked outside the home (1e7 times per week) compared
with never smokers (p¼0.035).
Clinical characteristics during asthma exacerbations
The clinical features during asthma exacerbations are reported in
table 3, and the separate clinical characteristics of mild and
severe exacerbations are given in the supplementary material
online. Severe exacerbations occurred in 52% of current smokers,
48% of ex-smokers and 35% of never smokers. Cumulative
exacerbations during pregnancy were higher in current smokers
than never smokers (p¼0.04, ﬁgure 1). The adjusted severe
exacerbation rate was also signiﬁcantly increased in smokers
(current, ex) (p¼0.001) and with increased BMI (p<0.0001) (see
online supplement).
When subjects’ ﬁrst exacerbation (mild or severe) was
analysed (table 3), current smokers had lower FENO during
exacerbation (compared with never and ex-smokers, p¼0.017)
and higher ECO during exacerbation (compared with never and
ex-smokers, p¼0.0001). The increase in FENO during subjects’
ﬁrst mild exacerbation was signiﬁcantly less in current smokers
(ﬁgure 2B), suggesting these were non-eosinophilic exacerba-
tions. For the ﬁrst severe exacerbation the FENO level (ﬁgure 2A)
and increase in FENO (ﬁgure 2B) were both low in all three
groups, indicating a high proportion of non-eosinophilic exac-
erbations. Current smokers had a median (IQR) increase in ECO
during exacerbations of 1 (0e4) ppm.
Current smokers had a non-signiﬁcantly higher ACQ6 during
exacerbation compared with never smokers (table 3, p¼0.056).
When the individual ACQ domains were analysed, wheeze was
higher in current smokers compared with never smokers, but
this did not reach signiﬁcance. The number of days of morning
symptoms reported by current smokers during exacerbation was
higher than by never smokers. Linear regression analysis indi-
cated that compared with never smokers, ACQ6 during exacer-
bation was signiﬁcantly increased in current smokers when
accounting for asthma severity, ICS use and women with
multiple exacerbations (p¼0.04) (online supplement). Ever
smoking compared with never smoking and increased BMI were
signiﬁcantly associated with the number of severe exacerbations
experienced by each individual in a Poisson regression model
(Supplementary table D).
Neonatal outcomes
Babies of current smokers were of lower mean birth weight 3207
(574) g than never 3479 (594) g or ex-smokers 3514 (470) g in
both the asthma and control groups (asthma, p¼0.0864; control,
p¼0.0232, ANOVA and TukeyeKramer multiple comparisons
test, never vs current smokers).
DISCUSSION
During pregnancy, asthma exacerbations among current
smokers are more frequent and more severe than those of never
smokers. Even though the smoking dose was relatively low, the
adverse effect of smoking was apparent, with a higher ACQ6,
increased wheeze and increased frequency of morning asthma
symptoms during exacerbations in current smokers. These
outcomes did not reach signiﬁcance possibly due to the small
sample size which is a limitation of this study. In addition the
rate of smoking among pregnant women with asthma was
higher than among controls. We found that 32% of pregnant
women with asthma smoked, while only 15% of control women
smoked. The consequences of this are the known adverse
outcomes for the fetus, particularly low birth weight, which we
have conﬁrmed, and more troublesome asthma. Together these
observations highlight the major importance of smoking by
women with asthma as a health problem during pregnancy.
The rate of smoking among pregnant women has been
declining in recent decades, and recent data showed that 17% of
Australian women smoked during pregnancy.2 Another study
also found that smokers were signiﬁcantly younger and more
Table 2 Passive smoke exposure
Asthma Control
Never smokers Ex-smokers Current smokers
p Value
Never smokers Ex-smokers Current smokers
p Valuen[25 n[27 n[22 n[24 n[27 n[21
Partner smokes 4 (16%)* 9 (33%)* 15 (68%) 0.001 6 (25%) 5 (33%) 3 (50%) NS
Smoking by others in household
Cigarettes/day 16.5 (11.25e20) 12.5 (6.25e22.5) 20 (12e20) NS 25 (12.5e30) 20 (16.3e23.8) 15 (15e18) NS
No. of others smoking n¼4 n¼10 n¼17 n¼6 n¼6 n¼5
Smoking allowed at home 17 (68%) 23 (85%) 20 (91%) NS 17 (71%) 11 (73%) 6 (100%) NS
Visitors smoking inside home: >1/week 0 (0%) 1 (5%) 3 (17%) NS 0 (0%) 1 (10%) 1 (25%) NS
Visitors smoking outside home: >1/week 4 (18%)* y 15 (56%) 15 (71%) 0.001 3 (20%) 6 (55%) 4 (80%) 0.035
*Post hoc test significant p<0.017 vs current smokers.
yvs ex smokers; NS, not significant.
Values are median (IQR) or n (%) of subjects within each group.
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likely to be single than non-smokers,29 and both studies used
maternal self-report to ascertain smoking history. Neonatal
outcomes are improved when women stop smoking early in
pregnancy. McCowan et al found that the rates of small for
gestational age infants and spontaneous preterm birth were
similar in non-smokers and those who quit before 15 weeks
gestation, while current smokers had three times the rate of
preterm birth and almost twice the rate of smaller babies than
non-smokers.29 There are no data available to assess whether
quitting smoking has any health beneﬁts on maternal asthma
and this should be an area of further research. In our study, those
smokers who had quit smoking (the ex-smoker group) had
a similar rate of severe exacerbations to the current smokers,
which was almost double that of the never smoker group. This
suggests the effect of smoking on asthma during pregnancy can
persist even after smoking cessation.
We assessed smoking status by self-report and measurement
of ECO. Pregnant women and mothers of young children are
a population group who may be reluctant to disclose their
smoking status to health professionals,30 especially midwives or
asthma educators. An ECO concentration of >9 ppm has been
used to indicate current smoking in pregnancy.31 In our study,
none of the never smokers or ex-smokers had a value this high at
visit 1, or during exacerbation, which provides some validation
for our self-reported assessment of smoking status. ECO values
are inﬂuenced by the time since last cigarette and may not detect
light smoking (12 current smokers had ECO values <9 ppm at
baseline or during exacerbation). Campbell et al assessed self-
reported smoking and ECO levels among antenatal clinic
attendees in Australia, a group of women similar to our partic-
ipants.31 They found that 23% of women self-reported smoking,
while a further 10% indicated that they had quit since becoming
pregnant. Only 3.3% of self-reported non-smokers had an ECO
reading $9 ppm. Half the smokers reported smoking <6 ciga-
rettes per day,31 similar to the levels of cigarette use reported in
our study. Therefore, our assessment of smoking status has
validity. Urinary or serum cotinine levels are more sensitive for
detecting active smoking, but were not measured in our study.
Pregnant women whose partner also smokes are twice as
likely to continue smoking into late pregnancy than other
smokers and recent quitters whose partner does not smoke.32
Our data on passive smoking among women with asthma
indicated that current smokers were signiﬁcantly more likely to
Table 3 Clinical features of asthma exacerbations (mild and severe) during pregnancy
Never smokers Ex-smokers Current smokers p Value
Events/person 1.5 (1e2) 2 (1e3) 2 (1e3) NS
Lung function at first exacerbation n¼13 n¼15 n¼18
FENO at exacerbation (ppb) 23.7 (17.9e39.2)* 22.7 (15.8e75.7)* 10.7 (6.8e18.2) 0.017
Increase in FENO (exacerbation) compared
with lowest (Dppb)
13.6 (6.1e16.6) 6.8 (2.3e47.0) 0.8 (0e5.8) NS
ECO at exacerbation (ppm) 1 (1e2)* 1 (1e1)* 8 (4e19) 0.0001
FEV1/FVC (%) at exacerbation 80.2 (75.0e89.4) 78.0 (70.2e83.7) 81.3 (74.7e86.1) NS
% predicted FEV1 at exacerbation 96.0 (84.7e102.6) 86.8 (77.8e106.2) 88.6 (77.2e103.0) NS
% predicted FVC at exacerbation 98.1 (91.2e105.1) 91.9 (88.3e113.3) 100.2 (84.8e105.5) NS
ACQ score at first exacerbation n¼21 n¼24 n¼21
Overall ACQ6 at exacerbation 1.17 (0.83e2.17) 1.67 (1.08e2.75) 2.17 (1.67e2.67) NS
Increase in ACQ (exacerbation) compared with
lowest (DACQ)
1 (1e1) 1 (0e2) 2 (1e2) NS
ACQ6 Domain 1 (Night waking) 1 (0e3) 2 (1e3) 2 (1e3) NS
ACQ6 Domain 2 (Morning symptoms) 2 (1e2) 2 (2e3) 2 (2e3) NS
ACQ6 Domain 3 (Activity limitation) 1 (0e2) 0.5 (0e2) 2 (1e3) NS
ACQ6 Domain 4 (Shortness of breath) 2 (1e3) 2 (1e3.5) 3 (2e3) NS
ACQ6 Domain 5 (Wheeze) 1 (0e2) 2 (1e3) 2 (2e4) NS
ACQ6 Domain 6 (Beta agonist use) 2 (1e2) 1 (1e2) 2 (1e3) NS
Symptoms during exacerbation n¼13 n¼15 n¼18
Night waking (nights in past week) 3 (0e6) 3 (2e7) 3.5 (2e5) NS
Morning symptoms (mornings in past week) 3 (2e4) 4 (0e7) 5.5 (3e7) NS
Activity limitation (days in past week) 2 (0e3) 0 (0e2) 2.5 (0e7) NS
Values are median (IQR) or n (%) of subjects in each group.
*Post hoc test significant p<0.017 vs current smokers.
ACQ, asthma control questionnaire; ECO, exhaled carbon monoxide; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NS, not significant.
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Figure 1 Asthma exacerbations during pregnancy in current smokers,
ex-smokers and never smokers. (A) Exacerbation rates of mild and
severe exacerbations per pregnancy. (B) Cumulative severe exacerba-
tions during pregnancy by smoking status. *p<0.02 current vs never
smokers.
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have a partner who smoked, more likely to allow smoking by
visitors and to be exposed to denser smoke in public places than
never smokers. Exposure to heavy environmental tobacco smoke
has been associated with worse asthma symptoms and greater
medication requirements in children.33 Interventions that target
tobacco avoidance in pregnancy need to focus on the household
as well as the patient, especially since the adverse effects of
smoking seem to occur with low dose tobacco exposure.
Cigarette smoking is associated with persistent changes in
asthma, including a more rapid decline of lung function with
age,20 poorer asthma control, reduced therapeutic response22 and
greater severity.24 In our study, baseline asthma control was not
signiﬁcantly different between never smokers and current
smokers. However, during exacerbation, asthma control was
worse in smokers than never smokers. This was driven by
a higher reported wheeze among current smokers during
exacerbation, as well as increased frequency of asthma symp-
toms on waking in the morning. A study of adult smokers with
asthma found that they had a signiﬁcantly increased ACQ (both
total score and individual answers for domains 1e6), but lung
function, measured by spirometry (and domain 7 of the ACQ),
was not different from the never smokers.21 The adults in this
study had had a 10 pack-year minimum and smoked an average
of 27 years. Both groups of subjects with asthma had a median
ACQ >1.5 (suggesting uncontrolled asthma), despite the fact
that they were considered to have been stable on treatment for
the past 4 weeks. In another study, the smokers (mean age 46;
25 pack-years) also had signiﬁcantly higher ACQ at baseline
(mean ACQ7¼1.9) compared with non-smokers (mean
ACQ7¼1.1).22 Both these groups of adults with asthma were
quite different from our cohort of pregnant women, who were
younger and had a much lower smoking dose; however, despite
this we also found that asthma symptoms were greater in
smokers with asthma. It appears that even smoking at a low
dose, or for a short duration has the potential to impact
adversely on asthma. The observation that forced expiratory
volume in 1 s (FEV1) is not (yet) reduced suggests an
opportunity for intervention before long-term lung function
change occurs.
The reasons for poorer asthma control among smokers,
particularly during exacerbation, may be related to medication
use, non-adherenc, or a direct effect of smoking on asthma
status. Current smokers were less likely to use ICS medications
during pregnancy and they also displayed poorer self-manage-
ment skills. Regression analysis indicated that asthma control
during exacerbation was increased among smokers even when
considering potential confounders such as ICS use, asthma
severity and multiple exacerbations, suggesting a direct effect of
smoking on asthma contributing to increased symptom severity.
It is known that smokers are relatively insensitive to cortico-
steroid treatment compared with non-smokers, possibly due to
non-eosinophilic inﬂammation.34 The low levels of FENO that
we observed during exacerbations are consistent with this. An
interaction between a direct smoking effect, or a reduced ther-
apeutic effect of ICS in smokers may cause the increase in
symptom severity.
Smokers had an increased ECO during mild exacerbations.
This suggests that there may be changes in smoking behaviour
associated with exacerbations. Increased cigarette consumption
during mild exacerbation may be causal in increasing symptoms
or decreasing treatment response which were used to detect
exacerbations. The absence of a change in FENO during exac-
erbations in smokers suggests that they experienced predomi-
nantly non-eosinophilic exacerbations, which may be less
responsive to corticosteroid treatment.
In conclusion, pregnant women with asthma who smoke
have exacerbations which are more severe and more frequent
than never smokers. Severe exacerbations during pregnancy are
a signiﬁcant risk factor for low birth weight,19 as is smoking
itself.1 Smoking cessation should be particularly encouraged in
pregnant women with asthma, as the effects of asthma on poor
perinatal outcomes may be greater among smokers than non-
smokers.
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FENO at Exacerbation




















Change in FENO during exacerbation



















Figure 2 Fractional exhaled nitric oxide (FENO) (A) and change in
FENO from the lowest value (B) during the first mild and first severe
asthma exacerbations during pregnancy in smokers, ex-smokers and
never smokers. *p<0.02 current vs never smoker.
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